General discussion, page-20228

First 20228 Last

Share
Profile

Follow
connor109

74 Posts.

2

14/09/24

15:17

Post #: 75675544
Share

Originally posted by UnclePanda: ↑

We will def see if it’s a pump and dump soon. But I don’t know whether your claim that the chaos ends when phase 3 starts is true.

“On August 8, 2024, Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR) announced that the FDA had approved LYMPHIR™ (denileukin diftitox-cxdl) for the treatment of relapsed or refractory (r/ cutaneous T-cell lymphoma after at least one prior systemic therapy”

CTXR have got FDA approval for their drug and is capped at $90M- they haven’t got any recognition from the market for even getting a drug through the FDA process

To compare to IHL, apnimed is bring a pill to treat OSA through the drug development process, so that’s huge competition for us. It has safety issues but it works according to its phase 2b results

the bottom line is, if IHL can’t get any recognition from the market at the moment and is totally written off, i can’t see how that will change when phase 2b results are released. Surely if big investors were interested, they would be showing signs into the news event like last time? This hasn’t happened and we are written off as another penny dreadful by the market

But you’re correct there’s room for multiple drugs - but there will be no unmet need and that will vastly reduce the potential pay of for IHL if we can get through the drug development process. That’s why I say, the best case for shareholders is breaking even and getting our money back. Management can just print themselves shares at ultra low prices and don’t have to worry about what the share price is to make money - they aren’t aligned with shareholders anymore which is a significant risk for shareholders

Expand

It is just like flipping a coin at this stage tbh. Although honestly if I am a big investor, I d wait for the results before investing any further to reduce risk.

IHL Price at posting: 4.1¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

HotCopper Highlights: Your most watched stocks for Week 46, 2024

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

First 20228 Last

Add IHL (ASX) to my watchlist

General discussion, page-20228

Top Stories

Cyclone signs MOU with Vale for development of Iron Bear play

Banshee's historic trenches prove rich in antimony and gold for GDM

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

HotCopper Highlights: Your most watched stocks for Week 46, 2024

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News